Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Differentiated human NBs are associated with better outcome and lower stage; induction of differentiation is considered to be therapeutically advantageous. All-trans retinoic acid (ATRA) has been shown to induce the differentiation of neuroblastoma (NB) cell lines. The proteasome inhibitor bortezomib inhibits cell growth and angiogenesis in NBs. Here, we investigated the synergistic effect between bortezomib and ATRA in inducing NB cell differentiation in different NB cell lines. Bortezomib combined with ATRA had a significantly enhanced antiproliferative effect. This inhibition was characterized by a synergistic increase in neuronal differentiation. At the same time, the combination therapy showed little neuronal toxicity which was assessed in primary cultures of rat cerebellar granule cells by the MTT assay, PI staining. The combination of bortezomib and ATRA triggered increased differentiation through the activation of proteins, including RARα, RARβ, RARγ, p-JNK and p21, compared with ATRA treatment alone. Using JNK inhibitor SP600125 to block JNK-dependent activity, the combination therapy-induced neuronal differentiation was partially attenuated. In addition, p21 shRNA had no effect on the combination therapy-induced neuronal differentiation. The in vivo antitumor activities were examined in human NB cell xenografts and GFP-labeled human NB cell xenografts. Treatment of human NB cell CHP126-bearing nude mice with ATRA plus bortezomib resulted in more significant tumor growth inhibition than mice treated with either drug alone. These findings provide the rationale for the development of a new therapeutic strategy for NB based on the pharmacological combination of ATRA and bortezomib.
References
[1]
Nowak D, Stewart D, Koeffler HP (2009) Differentation therapy of leukemia: 3 decades of development. Blood 113: 3655–3665.
[2]
Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1: 181–193.
[3]
Garattini E, Gianni M, Terao M (2007) Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr Pharm Des 13: 1375–1400.
[4]
De los Santos M, Zambrano A, Aranda A (2007) Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SHSY5Y cells. Mol Cancer Ther 6: 1425–1432.
[5]
Adamson PC, Matthay KK, O'BrienM , Reaman GH, Sato JK, et al. (2007) A phase 2 trial of all-trans-retinoic acid in combination with interferon-a2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group study. Pediatr Blood Cancer 49: 661–665.
[6]
Redova M, Chlapek P, Loja T, Zitterbart K, Hermanova M, et al. (2010) Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cells. Int J Mol Med 25: 271–280.
Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 17: 2264–2279.
[9]
Marimpietri D, Brignole C, Nico B, et al. (2007) Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res 13: 3977–3988.
[10]
van Noesel MM, Versteeg R (2004) Pediatric neuroblastomas: genetic and epigenetic ‘danse macabre'. Gene 325: 1–15.
[11]
Zhu J, Gianni M, Kopf E, Honoré N, Chelbi-Alix M, et al. (1999) Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α and oncogenic RARα fusion proteins. Proc Natl Acad Sci U S A 96: 14807–14812.
[12]
Nagai J, Yazawa T, Okudela K, Kigasawa H, Kitamura H, et al. (2004) Retinoic acid induces neuroblastoma cell death by inhibiting proteasomal degradation of retinoic acid receptor α. Cancer Res 64: 7910–7917.
[13]
Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons fromthe first decade. Clin Cancer Res 14: 1649–1657.
[14]
Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, et al. (2007) A phase 1study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 13: 1516–1522.
[15]
Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, et al. (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204: 317–325.
[16]
Wang D, Weng Q, Zhang L, He Q, Yang B (2009) VEGF and Bcl-2 interact via MAPKs signaling pathway in the response to hypoxia in neuroblastoma. Cell Mol Neurobiol 29: 391–401.
[17]
Veith NM, Plattner H, Stuermer CA, Schulz-Schaeffer WJ, Bürkle A (2009) Immunolocalisation of PrPSc in scrapie-infected N2a mouse neuroblastoma cells by light and electron microscopy. Eur J Cell Biol 88: 45–63.
[18]
Karlsson J, Pietras A, Beckman S, Pettersson HM, Larsson C, et al. (2007) Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax. Oncogene 26: 6150–6159.
[19]
Muth D, Ghazaryan S, Eckerle I, Beckett E, P？hler C, et al. (2010) Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res 70: 3791–3802.
[20]
Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, et al. (2005) Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 8: 723–729.
[21]
Luo PH, He QJ, He XG, Hu YZ, Lu W, et al. (2006) Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Molecular Cancer Therapeutics 5: 1–7.
[22]
Yang B, Reynolds CP (2005) Tirapazamine cytotoxicity for neuroblastoma is p53 dependent. Clin Cancer Res 1: 2774–2780.
[23]
Zhang C, Qu G, Sun Y, Yang T, Yao Z, et al. (2008) Biological evaluation of N-octyl-O-sulfate chitosan as a new nano-carrier of intravenous drugs. Eur J Pharm Sci 33: 415–423.
[24]
Murakami M, Ito H, Hagiwara K, Yoshida K, Sobue S, et al. (2010) ATRA inhibits ceramide kinase transcription in a human neuroblastoma cell line, SH-SY5Y cells: the role of COUP-TFI. J Neurochem 112: 511–520.
[25]
Mangelsdorf DJ, Evans RM (1995) The RXR heterodimers and orphan receptors. Cell 83: 841–850.
[26]
Pé rez-Juste G, Aranda A (1999) Differentiation of neuroblastoma cells by phorbol esters and insulin-like growth factor 1 is associated with induction of retinoic acid receptor gene β gene expression. Oncogene 18: 5393–5402.
[27]
Marshall GM, Cheung B, Stacey KP, Camacho ML, Simpson AM, et al. (1995) Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells. Oncogene 11: 485–491.
[28]
Nordstrom , EK , Luhr , KM , Ibanez , C , Kristensson K (2005) Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc. J Neurosci 25: 8451–8456.
[29]
Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, et al. (2005) p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 13: 1139–1144.
[30]
Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, et al. (2006) Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98: 1142–1157.
[31]
Liu Y, Kagechika H, Ishikawa J, Hirano H, Matsukuma S, et al. (2008) Effects of retinoic acids on the dendritic morphology of cultured hippocampal neurons. J Neurochem 106: 1104–1116.
[32]
Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362: 2202–2211.
[33]
Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367–1380.
[34]
Zhang L, Kavanagh BD, Thorburn AM, Camidge DR (2010) Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli. Clin Cancer Res 16: 4478–4489.
[35]
Soriano SG, Liu Q, Li J, Liu JR, Han XH et al (2010) Ketamine activates cell cycle signaling and apoptosis in the neonatal rat brain. Anesthesiology 112: 1155–1163.
[36]
Pang L, Sawada T, Decker SJ, Saltiel AR (1995) Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 270: 13585–13588.
[37]
Encinas M, Iglesias M, Llecha N, Comella JX (1999) Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J Neurochem 73: 1409–1421.
[38]
Washio A, Kitamura C, Jimi E, Terashita M, Nishihara T (2009) Mechanisms involved in suppression of NGF-induced neuronal differentiation of PC12 cells by hyaluronic acid. Exp Cell Res 315: 3036–3043.
[39]
Zhang J, Krishnamurthy PK, Johnson GV (2002) Cdk5 phosphorylates p53 and regulates its activity. J Neurochem 81: 307–313.
